Home
SLN
SLN News

Latest Silence Therapeutics Plc American Depository Share (SLN) News on November 17, 2025

MT Newswires

3 days ago

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

MT Newswires

4 days ago

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Business Wire

5 days ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

MT Newswires

7 days ago

European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading

Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates

Simply Wall St.

8 days ago

Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates

MT Newswires

11 days ago

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Business Wire

11 days ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

MT Newswires

14 days ago

European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading

MT Newswires

18 days ago

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

MT Newswires

25 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Business Wire

25 days ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Is Silence Therapeutics (NASDAQ:SLN) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

a month ago

Is Silence Therapeutics (NASDAQ:SLN) In A Good Position To Deliver On Growth Plans?

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading, Down 2.8% for Week

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires

2 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires

2 months ago

European Equities Traded in the US as ADRs Are Little Changed in Friday Trading

MT Newswires

2 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

GlobeNewswire

2 months ago

Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva

MT Newswires

5 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; Up 2.5% for Week

MT Newswires

5 months ago

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires

5 months ago

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

MT Newswires

5 months ago

Silence Therapeutics Says Diversiran Profile Remains 'Compelling' in Updated Data

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Business Wire

5 months ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

One Silence Therapeutics Insider Raised Stake By 15% In Previous Year

Simply Wall St.

5 months ago

One Silence Therapeutics Insider Raised Stake By 15% In Previous Year

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Silence Therapeutics (SLN) Could Surge 556.19%: Read This Before Placing a Bet

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

Zacks

6 months ago

Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

Simply Wall St.

6 months ago

Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks

We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate

Simply Wall St.

6 months ago

We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate

Silence Therapeutics First Quarter 2025 Earnings: Misses Expectations

Simply Wall St.

6 months ago

Silence Therapeutics First Quarter 2025 Earnings: Misses Expectations

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Business Wire

6 months ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Business Wire

6 months ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey

7 months ago

Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying

3 Promising Penny Stocks With Market Caps Under $200M

Simply Wall St.

7 months ago

3 Promising Penny Stocks With Market Caps Under $200M

Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Simply Wall St.

7 months ago

Silence Therapeutics plc (NASDAQ:SLN): When Will It Breakeven?

Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Simply Wall St.

8 months ago

Revenue Downgrade: Here's What Analysts Forecast For Silence Therapeutics plc (NASDAQ:SLN)

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Business Wire

8 months ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Zacks

8 months ago

Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

Silence Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Business Wire

9 months ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Business Wire

9 months ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

MT Newswires

9 months ago

Silence Therapeutics Shares Fall After Goldman Sachs Initiates Coverage at Sell

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Simply Wall St.

10 months ago

Institutional owners may take dramatic actions as Silence Therapeutics plc's (NASDAQ:SLN) recent 14% drop adds to one-year losses

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

Insider Monkey

a year ago

Silence Therapeutics plc (SLN): Among the Oversold Global Stocks to Buy Right Now

Insider Traders Lose UK£124k As Silence Therapeutics Drops

Simply Wall St.

a year ago

Insider Traders Lose UK£124k As Silence Therapeutics Drops

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Business Wire

a year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Business Wire

a year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Zacks

a year ago

SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Benzinga

a year ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Business Wire

a year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Silence Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

a year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Business Wire

a year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

Insider Monkey

a year ago

Is Silence Therapeutics plc (SLN) a Promising Gene Editing Stock?

We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

Simply Wall St.

a year ago

We're Hopeful That Silence Therapeutics (NASDAQ:SLN) Will Use Its Cash Wisely

MT Newswires

a year ago

Jefferies Initiates Silence Therapeutics at Buy With $40 Price Target

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Business Wire

a year ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

a year ago

Silence Therapeutics plc (NASDAQ:SLN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

a year ago

Silence Therapeutics Second Quarter 2024 Earnings: Misses Expectations

MT Newswires

a year ago

Silence Therapeutics' Q2 Loss Widens as Revenue Falls

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Business Wire

a year ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain

Simply Wall St.

a year ago

Institutional investors are Silence Therapeutics plc's (NASDAQ:SLN) biggest bettors and were rewarded after last week's US$76m market cap gain

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

Zacks

a year ago

Silence Therapeutics (SLN) Moves 5.8% Higher: Will This Strength Last?

MT Newswires

a year ago

Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating

MT Newswires

a year ago

Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating

MT Newswires

a year ago

Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Business Wire

a year ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Business Wire

a year ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Business Wire

a year ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

One Silence Therapeutics Insider Raised Their Stake In The Previous Year

Simply Wall St.

a year ago

One Silence Therapeutics Insider Raised Their Stake In The Previous Year

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Business Wire

a year ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Silence Therapeutics (NASDAQ:SLN) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Silence Therapeutics (NASDAQ:SLN) Is In A Good Position To Deliver On Growth Plans

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Business Wire

2 years ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Business Wire

2 years ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Business Wire

2 years ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?

Zacks

2 years ago

Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Business Wire

2 years ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results

Simply Wall St.

2 years ago

Analysts Are Upgrading Silence Therapeutics plc (NASDAQ:SLN) After Its Latest Results

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Silence Therapeutics plc (NASDAQ:SLN) Q4 2023 Earnings Call Transcript

Silence Therapeutics Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

2 years ago

Silence Therapeutics Full Year 2023 Earnings: Misses Expectations

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Business Wire

2 years ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Business Wire

2 years ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?

Zacks

2 years ago

MediWound (MDWD) Moves 7.1% Higher: Will This Strength Last?

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks

2 years ago

Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Business Wire

2 years ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Business Wire

2 years ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?

Zacks

2 years ago

Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?

Broker Revenue Forecasts For Silence Therapeutics plc (NASDAQ:SLN) Are Surging Higher

Simply Wall St.

2 years ago

Broker Revenue Forecasts For Silence Therapeutics plc (NASDAQ:SLN) Are Surging Higher

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Business Wire

2 years ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2023 Earnings Call at 8:30 a.m. on Wednesday, February 21, 2024

GlobeNewswire

2 years ago

Shenandoah Telecommunications Company to Hold its Fourth Quarter and Full Year 2023 Earnings Call at 8:30 a.m. on Wednesday, February 21, 2024

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Business Wire

2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Hamilton Lane (HLNE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

2 years ago

Hamilton Lane (HLNE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AMERANT BANK PROVIDES FINANCING TO FRESCO RETAIL GROUP, LLC FOR THE ACQUISITION OF FRESCO Y MÁS OPERATIONS AND LOCATIONS

GlobeNewswire

2 years ago

AMERANT BANK PROVIDES FINANCING TO FRESCO RETAIL GROUP, LLC FOR THE ACQUISITION OF FRESCO Y MÁS OPERATIONS AND LOCATIONS

Allegiant Reports December 2023 Traffic

PR Newswire

2 years ago

Allegiant Reports December 2023 Traffic

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Dips More Than Broader Market: What You Should Know

Zacks

2 years ago

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Dips More Than Broader Market: What You Should Know

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation

Business Wire

2 years ago

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Stock Sinks As Market Gains: What You Should Know

Zacks

2 years ago

Loma Negra Compania Industrial Argentina S.A. Sponsored ADR (LOMA) Stock Sinks As Market Gains: What You Should Know

Share on Social Networks: